PHARMACY

Los Angeles pharmacies report no quake damage

BY Doug Desjardins

LOS ANGELES A 5.4 magnitude earthquake shook Los Angeles on Tuesday but caused no injuries or damage at area drug stores, though a few CVS stores were forced to shut down temporarily.

“A couple of our stores were closed temporarily to clean up merchandise that fell off the shelves during the quake,” said CVS director of public relations Mike DeAngelis. “But we haven’t received any reports of stores significantly damaged by today’s earthquake.”

As of 3:30 p.m. PT on Tuesday, none of the major area retailers including Walgreens, Rite-Aid and Longs Drug reported any damage to stores. The quake centered in the Chino Hills area outside Los Angeles caused some water mains to break but no major structural damage to bridges, buildings or roads. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Eisai receives not approvable letter for Aquavan

BY Alaric DeArment

NEW YORK The Food and Drug Administration has denied approval for a sedative for patients receiving minor medical procedures, according to published reports Friday.

The FDA sent Eisai a not-approvable letter for Aquavan, citing insufficient evidence showing that health-care providers without training in general anesthesia could use it safely.

Aquavan (fospropofol disodium injection) was developed by MGI Pharma, which Eisai bought for $3.9 billion in January.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Sanofi-Aventis to acquire Acambis in $550 million deal

BY Alaric DeArment

NEW YORK French drug maker Sanofi-Aventis will buy United Kingdom-based Acambis in an agreement announced Friday.

Sanofi-Aventis will pay $550.7 million for the British vaccine maker, or $3.79 a share.

Sanofi-Aventis has had a partnership with Acambis since November through its subsidiary, Sanofi Pasteur. The two companies were commercializing vaccines against dengue fever, Japanese encephalitis and West Nile virus. Acambis is also developing vaccines against flu and herpes and won a 10-year, $425 million contract with the United States government to supply a smallpox vaccine.

“This mutually beneficial acquisition is a logical step building upon Sanofi Pasteur and Acambis’ decade-long partnership on key projects to develop and market vaccines of the future,” stated Wayne Pisano, chief executive officer of Sanofi Pasteur.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES